HSBC cuts Lilly target to $850, appoints new Continental Europe CEO
HSBC's research arm cut its Eli Lilly price target to $850 from $1,070, citing inflated obesity drug market expectations and intensifying price competition. The bank appointed a new CEO for its Continental Europe unit and highlighted a 10% bonus pool increase, contrasting with 30-50% cuts at Chinese state banks.
1. HSBC downgrades Eli Lilly
HSBC analyst Rajesh Kumar downgraded Eli Lilly to Reduce and slashed the price target from $1,070 to $850. The bank flagged three key risks: obesity drug market TAM expectations inflated above $150 billion, looming price competition and 2026 price cuts, and potential underperformance of Lilly’s oral obesity drug launch tied to a cash-pay channel.
2. Divergent bonus practices in banking
Chinese state-backed banks are cutting senior bonuses by 30% to 50% under Xi’s pay reform push, while HSBC and Standard Chartered have increased bonus pools by about 10%. The contrast reflects regulatory efforts in China to curb excessive pay and promote common prosperity, even as global peers seek to retain talent.
3. CEO appointment for Continental Europe
HSBC announced the appointment of a new CEO for its Continental Europe unit, marking a leadership transition for its European operations. The incoming executive will oversee strategic growth initiatives, regulatory compliance and integration of regional business lines.